Supporting at-risk mothers across perinatal period: a randomized controlled trial' (SMART): A development study.

MidwiferyMay 20, 2026 (epub)
Clinical ResearchObstetrics & GynecologyPsychiatry

Lubna Shah, Joelle Yan Xin Chua, Aayisha Aayisha et al.

✦ AI-curated · Sources linked

In 30 seconds

The SMART study is a randomized controlled trial that developed a mobile health application aimed at supporting at-risk mothers during the perinatal period. The intervention was designed based on user needs and included features such as educational content and peer support. User acceptance testing with 21 perinatal women showed favorable ratings for app quality and usability.

Key findings

  • User acceptance testing indicated favorable ratings for app quality, information quality, and usability.
  • The intervention included features like an activity hub, peer support chat, and a gratitude journal.
  • Participant feedback led to refinements in content presentation and resource accessibility.

Why it matters

Supporting at-risk mothers during the perinatal period is crucial for improving maternal and infant health outcomes. Mobile health interventions can provide accessible resources and peer support, potentially mitigating the risk of depression.

Source

PubMed · PMID 42208363

Published in Midwifery. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.